PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Cutaneous lupus erythematosus

Drugs in development · updated 30 October 2026

Cutaneous lupus erythematosus: drugs in development

As of 30 October 2026 there are 19 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for cutaneous lupus erythematosus. 12 are experimental, that is not yet approved in the United States.

19Active trials
12Experimental drugs
3Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
EnpatoranM5049III4NCT07355218
LitifilimabBIIB059II–III2NCT05531565
AfimetoranII–III1NCT07881120
DB-2304I–II1NCT06625671
ICP-488II1NCT07440537
IMVT-1402II1NCT06980805
Quinacrine HydrochlorideII1NCT07694336
VENT-03II1NCT07260877
ACT100I1NCT07408908
HC022I1NCT07306585
S-4321I1NCT07455578
SHR-7012I1NCT07749651

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
LenalidomideRevlimid, lenalinomideIII1NCT06965244
MethotrexateJylamvo®, Reditrex®III1NCT06965244
DeucravacitinibBMS-986165, Sotyktu®II1NCT04857034
PrednisonePredinisone, CortancylI–II1NCT06625671
TapinarofBenvitimod Cream, Vtama®Early I1NCT06661213

Sorted by most advanced phase and number of active trials.

All 17 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008178 “Lupus Erythematosus, Cutaneous”.

ItalianoFrançaisDeutsch